Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Califf Previews US FDA’s Authorization Rationale For COVID Bivalent Boosters

Aug 26 2022

• By Nielsen Hobbs and Pink Sheet Team

• Source: Shutterstock

Related Content

Next-Gen Vaccine Makers Want Up-Front Discussions With US FDA To Expedite Development

Aug 26 2022

Moderna Lauds Joint Work With Health Authorities On Spikevax Safety Monitoring

Aug 24 2022

Overhyped? White House COVID Coordinator's Claims About New Boosters Go Beyond Data

Aug 18 2022

Moderna Looks To Catch Up In COVID-19 For Kids, While Still Branching Out In Other Areas

Mar 23 2022

Pfizer Strengthens Foundation For A Long-Term COVID Commercial Business

Jul 28 2022

Novavax’s COVID-19 Shot Finally Authorized In US, But Could Miss Out Again On Bivalent Booster

Jul 15 2022

Valneva Confirms Step Back From COVID-19 Vaccine Development

Aug 12 2022

COVID Vaccines In Young Children: FDA, Sponsors Estimated Benefits Against Unclear Myocarditis Risk

Jul 13 2022

US FDA Advisors' Push For BA.4/BA.5 COVID-19 Boosters Sets Up Regulatory, Manufacturing Crunch

Jun 29 2022

US FDA Appears To Quickly Renege On Next-Gen COVID Vaccine Guidance With Updated Booster Announcement

Jul 01 2022

UK First To Approve Moderna’s Bivalent COVID-19 Vaccine

Aug 15 2022

US FDA Bypasses Adcomm In Authorizing Second COVID Booster Because Decision ‘Straight-Forward’

Mar 30 2022

Related Companies

Pfizer Inc.

BioNTech SE

Moderna, Inc.

Novavax, Inc.

Valneva SE

Additional Topics

United States Coronavirus COVID-19 Vaccines Research & Development Advisory Committees Regulation Infectious Diseases BioPharmaceutical

More from Vaccines

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window